Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project

Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project

Venous thromboembolism (VTE) is a major cause of death in the world. After the acute-phase treatment, the optimal duration of anticoagulation is still debatable. The latest guidelines suggest maintaining long-term anticoagulation in patients with cancer-associated thrombosis (CAT) or with unprovoked...

Full description

Bibliographic Details
Main Authors: Cristiano Bortoluzzi, Enrico Bernardi, Giuseppe Camporese, Franco Noventa, Davide Ceccato, Chiara Tonello, Ngoc Vo Hong, Elena Campello, Chiara Simion, Egidio Imbalzano, Pierpaolo Di Micco, Elena Callegari, Paolo Simioni
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Life
Subjects:
venous thromboembolism
long-term anticoagulation
rivaroxaban
Online Access:https://www.mdpi.com/2075-1729/12/10/1657

Internet

https://www.mdpi.com/2075-1729/12/10/1657

Similar Items